Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 8/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | UBE2M | P61081 | 1/20 | 0.43 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | GCGR | P47871 | 2/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | LIPE | Q05469 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
| ▸ | NPY2R | P49146 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7724270 | 0.86 | ACHE (0.57) | EPHX2KDM4EALDH1A1POLBUBE2M | |
| SCHEMBL7966338 | 0.79 | P2RY1 (0.48) | EPHX2KDM4EALDH1A1POLB | |
| SCHEMBL6497878 | 0.75 | PKM (0.47) | UBE2MDCUN1D1ACHE | |
| SCHEMBL6486577 | 0.73 | CCR2 (0.50) | EPHX2ACHEKMT2A | |
| SCHEMBL25991218 | 0.70 | KMT2A (0.53) | EPHX2KDM4EALDH1A1POLBKMT2A | |
| SCHEMBL6500642 | 0.69 | DCUN1D1 (0.55) | UBE2MDCUN1D1 | |
| SCHEMBL6486209 | 0.66 | EPHX1 (0.42) | EPHX2UBE2MDCUN1D1ACHEKMT2A | |
| SCHEMBL13873288 | 0.65 | EPHX2 (1.00) | EPHX2KDM4EALDH1A1POLBACHE | |
| SCHEMBL1941707 | 0.64 | EPHX2 (0.65) | EPHX2POLBACHEKMT2A | |
| SCHEMBL6287578 | 0.64 | NR3C1 (0.49) | EPHX2ACHESCN9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6946477-B2 | 3-Substituted piperidines comprising urea functionality, and methods of use thereof | SEPRACOR INC. (US) | 2005-09-20 | — | — | US | disclosed |
| US-20030114436-A1 | 3-substituted piperidines comprising urea functionality, and methods of use thereof | AQUILA BRIAN M (US) | 2003-06-19 | — | — | US | disclosed |
| US-6476050-B2 | ANALGESICS; LIGANDS FOR VARIOUS CELLULAR RECEPTORS, INCLUDING OPIOID RECEPTORS, OTHER G-PROTEIN-COUPLED RECEPTORS AND ION CHANNELS | SEPRACOR, INC. | 2002-11-05 | — | — | US | disclosed |
| US-20010056090-A1 | 3-substituted piperidines comprising urea functionality, and methods of use thereof | SEPRACOR INC. | 2001-12-27 | — | — | US | disclosed |
| WO-2001068604-A2 | 3-SUBSTITUTED PIPERIDINES COMPRISING UREA FUNCTIONALITY, AND METHODS OF USE THEREOF | SEPRACOR, INC. (US) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056090-A1 | 3-substituted piperidines comprising urea functionality, and methods of use thereof | OPRM1, OPRL1, OPRK1 | EPHX2 1187/4885KDM4E 3251/4885ALDH1A1 1031/4885 |
| US-20030114436-A1 | 3-substituted piperidines comprising urea functionality, and methods of use thereof | OPRM1, OPRL1, OPRK1 | EPHX2 1187/4885KDM4E 3251/4885ALDH1A1 1031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.